MedTrace Logo

A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis

NCT01737372 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2016-11-09

No results posted yet for this study

Summary

This study will look at the blood and cerebrospinal fluid of consented participants who either have early stage multiple sclerosis (clinically isolated syndrome) or who have later stage (secondary progressive multiple sclerosis), or participants who do not have any neurological or autoimmune illness. Biomarkers and microRNA will be assessed for group differences.

Conditions

  • Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis
  • Clinically Isolated Syndrome

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY

  • John F. Foley, MD

    lead OTHER

Principal Investigators

  • John F Foley, MD · Rocky Mountain MS Research Group, LLC

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01737372 on ClinicalTrials.gov